Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma

Oncol Rep. 2007 Dec;18(6):1373-7.


In spite of recent advances in the treatment of retinoblastoma, chemotherapy is still challenging in high-stage intraocular retinoblastoma or metastatic retinoblastoma. Here, we investigated whether arginine deprivation via arginine deiminase (ADI) could be a new anti-tumor therapy in retinoblastoma cells. Expression of argininosuccinate synthetase (ASS) was detected in human retinoblastoma tissues. Even with a high expression of ASS, ADI effectively inhibited the proliferation of retinoblastoma cells and induced retinoblastoma cell death in a dose-dependent manner. These results indicate that arginine deprivation via ADI could be another treatment option for retinoblastoma due to low ASS activity in retinoblastoma cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma
  • Antineoplastic Agents / therapeutic use*
  • Arginine / metabolism*
  • Argininosuccinate Synthase / genetics
  • Argininosuccinate Synthase / metabolism
  • Breast Neoplasms
  • Cell Division
  • Cell Line, Tumor
  • Cell Survival
  • Eye Enucleation
  • Eye Neoplasms / enzymology
  • Eye Neoplasms / pathology
  • Eye Neoplasms / surgery
  • Female
  • Humans
  • Hydrolases / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Retinoblastoma / enzymology
  • Retinoblastoma / pathology
  • Retinoblastoma / surgery


  • Antineoplastic Agents
  • Recombinant Proteins
  • Arginine
  • Hydrolases
  • arginine deiminase
  • Argininosuccinate Synthase